Clinical Trial Update: Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing TAK-700 in combination with docetaxel and prednisone for metastatic castration-resistant prostate cancer has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)
• TAK-700 (Orteronel)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-30